CEM acquires key assets of Intavis Bioanalytical Instruments
CEM Corporation announced that it has entered into a definitive agreement to purchase the instrumentation lines of Intavis Bioanalytical Instruments AG, with headquarters in Cologne Germany. The acquisition allows CEM to strengthen its product offering in the Life Sciences for proteomics, in-situ hybridization and particularly in the field of peptide synthesis.
CEM
The Intavis instrumentation provides unique robotic synthesis technology that is very complementary to CEM’s line of microwave peptide synthesizers. In particular, this includes small scale highly-parallel formats for making peptides either on resins or membranes, which allow for direct screening. In contrast, CEM’s peptide synthesis technology provides extremely rapid and efficient peptide production at larger scales. With this acquisition, customers will now benefit from a complete portfolio of peptide synthesis technology available through CEM’s large global support network.
“We are very pleased to be acquiring the Intavis line of instruments and unique robotic technology. Strategically, it will expand CEM’s capabilities to fully support the development of peptide based therapeutics from early stage lead identification to preclinical and cGMP commercialization. In addition, this technology creates new bioscience sample preparation opportunities for CEM.” said Michael J. Collins, President and CEO of CEM.
Dr. Steffen Huettner, CEO of Intavis commented “We are proud to work together with CEM. This agreement enables a great future for the Intavis technologies and opens our company to focus on new developments”
During the transition, which is expected to last 4 months, Intavis will continue to sell and support their products. After the transition period, CEM will manufacture the Intavis instruments at their global headquarters in Matthews, NC. CEM will also assume full responsibility for sales, support, and service for all existing Intavis customers using its global support system.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
Last viewed contents
A new way to stimulate cellular recycling process
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement - Offer price increased
New insights into the function of a risk factor for Alzheimer’s disease - Researchers decipher the structure-function relationship of the multifunctional protein clusterin for the first time
Rigaku opens Rigaku Technology Center Taiwan - Advancing regional growth through engineering and collaboration in Taiwan and beyond
Multiplexed Morse signals from cells
Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Closing in on the elusive rotational-vibrational CH5+ spectra
New model predicts a chemical reaction’s point of no return - Chemists could use this quick computational method to design more efficient reactions that yield useful compounds, from fuels to pharmaceuticals
Fondant under the magnifying glass - New insights into the properties of sweet coating: The results could be used to optimize the industrial production process in the future
